Fapon Highlights Innovative IVD Total Solutions and Localization Services

By LabMedica International staff writers
Posted on 13 Nov 2024

Image

Fapon Biotech (Guangdong, China) is participating in MEDICA 2024 where the company is showcasing its IVD total solutions, including IVD raw materials, reagent services, and open-system instruments. Additionally, the company is introducing its technology transfer and local manufacturing services to best underscore its commitment to quality and customer satisfaction.

At this year’s MEDICA, Fapon is presenting a suite of total solutions across various technology applications, including CLIA, biochemistry, NGS, PCR, LFA, and FIA for both clinical diagnostic labs and POCT scenarios. Leveraging its strong foundation in IVD technologies, Fapon integrates raw materials, reagent services, and open-system instruments into IVD total solutions. This approach ensures reliable, versatile, and seamless services for its IVD partners, particularly local IVD companies and distributors that are establishing or expanding their own IVD production lines. Ultimately, these efforts benefit local hospitals and patients. Fapon's goal is to elevate the portfolios of global IVD manufacturers through technology transfer and local manufacturing.

Fapon's chemiluminescence immunoassay product line being highlighted at the show exemplifies its expertise in IVD total solutions, including the Shine i-series open-system CLIA analyzers for low- to ultra-high-throughput testing, alongside over 70 reagent services for assay such as vitamin D, NT-proBNP, hs-cTnI, PCT and AD. In addition, Fapon is presenting its molecular POCT total solutions and immunofluorescence POCT total solutions, which feature fully automated molecular diagnostic analyzers, immunofluorescence POCT quantitative analyzers, and reagent services, collectively reflecting the company’s commitment to advancing diagnostic technologies for the unique needs of the IVD industry.

Fapon is committed to delivering high-performance IVD core raw materials that meet European market demands. The company’s offerings of animal-origin-free IVD raw materials address stringent market requirements and ethical considerations. Recently, Fapon launched an innovative sandwich immunoassay format for vitamin D using its high-quality raw materials, achieving superior performance and correlation compared to competitive assays. Furthermore, Fapon remains agile in meeting emerging diagnostic needs, providing testing raw materials for prevalent diseases such as SCD, mpox, and H5N1. With a strong focus on respiratory and infectious disease diagnostics, Fapon ensures its customers have access to the high-quality raw materials needed to support effective diagnostics and patient care. At MEDICA 2024, Fapon is showcasing its role as a trusted global partner in the IVD industry while meeting industry professionals, sharing insights, and exploring collaborations that drive innovation forward and improve healthcare outcomes.

Related Links:
Fapon Biotech